|
1
|
Rachner TD, Khosla S and Hofbauer LC:
Osteoporosis: Now and the future. Lancet. 377:1276–1287. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Venken K, Callewaert F, Boonen S and
Vanderschueren D: Sex hormones, their receptors and bone health.
Osteoporos Int. 19:1517–1525. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Makras P, Delaroudis S and Anastasilakis
AD: Novel therapies for osteoporosis. Metabolism. 64:1199–1214.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lindberg MK, Erlandsson M, Alatalo SL,
Windahl S, Andersson G, Halleen JM, Carlsten H, Gustafsson JA and
Ohlsson C: Estrogen receptor alpha, but not estrogen receptor beta,
is involved in the regulation of the OPG/RANKL
(osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and
serum interleukin-6 in male mice. J Endocrinol. 171:425–433. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boyce BF and Xing L: Functions of
RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem
Biophys. 473:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Silva I and Branco JC: Rank/Rankl/opg:
Literature review. Acta Reumatol Port. 36:209–218. 2011.PubMed/NCBI
|
|
7
|
Lacey DL, Boyle WJ, Simonet WS, Kostenuik
PJ, Dougall WC, Sullivan JK, San Martin J and Dansey R: Bench to
bedside: Elucidation of the OPG-RANK-RANKL pathway and the
development of denosumab. Nat Rev Drug Discov. 11:401–419. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eghbali-Fatourechi G, Khosla S, Sanyal A,
Boyle WJ, Lacey DL and Riggs BL: Role of RANK ligand in mediating
increased bone resorption in early postmenopausal women. J Clin
Invest. 111:1221–1230. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Woo KM, Choi Y, Ko SH, Ko JS, Oh KO and
Kim KK: Osteoprotegerin is present on the membrane of osteoclasts
isolated from mouse long bones. Exp Mol Med. 34:347–352. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kondo T, Kitazawa R, Maeda S and Kitazawa
S: 1 Alpha, 25 dihydroxyvitamin D3 rapidly regulates the mouse
osteoprotegerin gene through dual pathways. J Bone Miner Res.
19:1411–1419. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anderson DM, Maraskovsky E, Billingsley
WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D
and Galibert L: A homologue of the TNF receptor and its ligand
enhance T-cell growth and dendritic-cell function. Nature.
390:175–179. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsu H, Lacey DL, Dunstan CR, Solovyev I,
Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, et
al: Tumor necrosis factor receptor family member RANK mediates
osteoclast differentiation and activation induced by
osteoprotegerin ligand. Proc Natl Acad Sci USA. 96:3540–3545. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hofbauer LC, Khosla S, Dunstan CR, Lacey
DL, Spelsberg TC and Riggs BL: Estrogen stimulates gene expression
and protein production of osteoprotegerin in human osteoblastic
cells. Endocrinology. 140:4367–4370. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bord S, Ireland DC, Beavan SR and Compston
JE: The effects of estrogen on osteoprotegerin, RANKL, and estrogen
receptor expression in human osteoblasts. Bone. 32:136–141. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saika M, Inoue D, Kido S and Matsumoto T:
17beta-estradiol stimulates expression of osteoprotegerin by a
mouse stromal cell line, ST-2, via estrogen receptor-alpha.
Endocrinology. 142:2205–2212. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Manokawinchoke J, Ritprajak P, Osathanon T
and Pavasant P: Estradiol induces osteoprotegerin expression by
human dental pulp cells. Odontology. 104:10–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bekker PJ, Holloway D, Nakanishi A,
Arrighi M, Leese PT and Dunstan CR: The effect of a single dose of
osteoprotegerin in postmenopausal women. J Bone Miner Res.
16:348–360. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Michael H, Härkönen PL, Väänänen HK and
Hentunen TA: Estrogen and testosterone use different cellular
pathways to inhibit osteoclastogenesis and bone resorption. J Bone
Miner Res. 20:2224–2232. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rumpler M, Varga F and Nemeth P:
Identification of an estrogen response element in the
osteoprotegerin promoter. Bone. 33:S17
|
|
20
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:287–297. 2004.
View Article : Google Scholar
|
|
21
|
Hassan MQ, Tye CE, Stein GS and Lian JB:
Non-coding RNAs: Epigenetic regulators of bone development and
homeostasis. Bone. 81:746–756. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jia J, Tian Q, Ling S, Liu Y, Yang S and
Shao Z: MiR-145 suppresses osteogenic differentiation by targeting
Sp7. FEBS Lett. 587:3027–3031. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fukuda T, Ochi H, Sunamura S, Haiden A,
Bando W, Inose H, Okawa A, Asou Y and Takeda S: MicroRNA-145
regulates osteoblastic differentiation by targeting the
transcription factor Cbfb. FEBS Lett. 589:3302–3308. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang N, Wang G, Hu C, Shi Y, Liao L, Shi
S, Cai Y, Cheng S, Wang X, Liu Y, et al: Tumor necrosis factor α
suppresses the mesenchymal stem cell osteogenesis promoter miR-21
in estrogen deficiency-induced osteoporosis. J Bone Miner Res.
28:559–573. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen C, Cheng P, Xie H, Zhou HD, Wu XP,
Liao EY and Luo XH: MiR-503 regulates osteoclastogenesis via
targeting RANK. J Bone Miner Res. 29:338–347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pitari MR, Rossi M, Amodio N, Botta C,
Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT,
Arbitrio M, et al: Inhibition of miR-21 restores RANKL/OPG ratio in
multiple myeloma-derived bone marrow stromal cells and impairs the
resorbing activity of mature osteoclasts. Oncotarget.
6:27343–27358. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Prossnitz ER, Arterburn JB, Smith HO,
Oprea TI, Sklar LA and Hathaway HJ: Estrogen signaling through the
transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol.
70:165–190. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bashir A, Mak YT, Sankaralingam S, Cheung
J, McGowan NW, Grigoriadis AE, Fogelman I and Hampson G: Changes in
RANKL/OPG/RANK gene expression in peripheral mononuclear cells
following treatment with estrogen or raloxifene. Steroids.
70:847–855. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rachner TD, Schoppet M, Niebergall U and
Hofbauer LC: 17beta-Estradiol inhibits osteoprotegerin production
by the estrogen receptor-alpha-positive human breast cancer cell
line MCF-7. Biochem Biophys Res Commun. 368:736–741. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Castellano L, Giamas G, Jacob J, Coombes
RC, Lucchesi W, Thiruchelvam P, Barton G, Jiao LR, Wait R, Waxman
J, et al: The estrogen receptor-alpha-induced microRNA signature
regulates itself and its transcriptional response. Proc Natl Acad
Sci USA. 106:15732–15737. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klinge CM: Estrogen regulation of MicroRNA
expression. Curr Genomics. 10:169–183. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Klinge CM: miRNAs regulated by estrogens,
tamoxifen, and endocrine disruptors and their downstream gene
targets. Mol Cell Endocrinol. 418:273–297. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sachdeva M and Mo YY: miR-145-mediated
suppression of cell growth, invasion and metastasis. Am J Transl
Res. 2:170–180. 2010.PubMed/NCBI
|
|
35
|
Hu H, Zhang Y, Cai XH, Huang JF and Cai L:
Changes in microRNA expression in the MG-63 osteosarcoma cell line
compared with osteoblasts. Oncol Lett. 4:1037–1042. 2012.PubMed/NCBI
|
|
36
|
Li E, Zhang J, Yuan T and Ma B: MiR-145
inhibits osteosarcoma cells proliferation and invasion by targeting
ROCK1. Tumour Biol. 35:7645–7650. 2014. View Article : Google Scholar : PubMed/NCBI
|
